New updates have been reported about Ro.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ro is deepening its position in the fast-growing GLP-1 weight-loss market by working with Eli Lilly to roll out the newly FDA-approved Zepbound (tirzepatide) KwikPen across its national telehealth platform, giving patients access to a multi-dose pen version of what is currently considered the most effective GLP-1 therapy. Through Ro.co, cash-pay patients can obtain the KwikPen alongside integrated clinical services, including continuous messaging with providers, one-on-one coaching, educational support, weight and dose tracking, and monitoring for side effects.
The collaboration builds on Ro’s December 2024 integration with Eli Lilly’s direct-to-patient channel, through which Ro has helped speed the introduction of new Zepbound delivery formats while maintaining the lowest available cash prices. Pricing for Zepbound via Ro starts at $299 per month for the 2.5 mg starter dose and $399 for the 5 mg dose, with higher doses (7.5–15 mg) available at a manufacturer-discounted $449 per month when patients refill within 45 days, and more than 2 million people have already used Ro’s GLP-1 Insurance Checker to evaluate coverage and optimize out-of-pocket costs.